Skip to search formSkip to main contentSkip to account menu

Bupropion

Known as: Amfebutamone, (+-)-1-(3-Chlorophenyl)-2-((1,1-dimethylethyl)amino)-1-propanone, BUP 
An aminoketone with antidepressant activity. The molecular mechanism of the antidepressant effect of bupropion is unknown. This agent does not… 
National Institutes of Health

Related topics

Related topics

39 relations
12 HR Bupropion Hydrochloride 100 MG Extended Release Oral Tablet [Wellbutrin]12 HR Bupropion Hydrochloride 150 MG Extended Release Oral Tablet24 HR Bupropion Hydrochloride 300 MG Extended Release Oral Tablet [Wellbutrin]24 HR Bupropion hydrobromide 348 MG Extended Release Oral Tablet [Aplenzin]
Expand

Broader (5)

Antidepressive AgentsAntidepressive Agents, Second-GenerationBupropion HydrochlorideCytochrome P-450 CYP2D6 Inhibitors
Expand

Narrower (9)

AplenzinBudeprionContraveQuomen
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2009
Review
2009
Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis
Highly Cited
2006
Highly Cited
2006
Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.
BACKGROUND After unsuccessful treatment for depression with a selective serotonin-reuptake inhibitor (SSRI), it is not known… 
Highly Cited
2006
Highly Cited
2006
Efficacy of Varenicline, an 42 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking Cessation A Randomized Controlled Trial
ContextVarenicline, a partial agonist at the α4β2 nicotinic acetylcholine receptor, has the potential to aid smoking cessation by… 
Highly Cited
2006
Highly Cited
2006
Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation: A Randomized Controlled Trial
ContextThe α4β2 nicotinic acetylcholine receptors (nAChRs) are linked to the reinforcing effects of nicotine and maintaining… 
Highly Cited
2004
Highly Cited
2004
Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design.
Highly Cited
2003
Highly Cited
2003
Nicotine replacement therapy in smoking cessation.
Evidence for benefit from nicotine replacement therapy in hospital patients is inconclusive, although the results of a trial… 
Highly Cited
2000
Highly Cited
2000
Bupropion is a nicotinic antagonist.
Neuronal nicotinic receptors are ligand-gated ion channels of the central and peripheral central nervous system that regulate… 
Highly Cited
1999
Highly Cited
1999
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.
BACKGROUND AND METHODS Use of nicotine-replacement therapies and the antidepressant bupropion helps people stop smoking. We… 
Highly Cited
1997
Highly Cited
1997
A Comparison of Sustained-Release Bupropion and Placebo for Smoking Cessation
Background and Methods Trials of antidepressant medications for smoking cessation have had mixed results. We conducted a double… 
Review
1995
Review
1995
Bupropion: a review of its mechanism of antidepressant activity.
BACKGROUND The mechanism of action of the novel antidepressant bupropion remains unclear after many years of study. A review of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License